AVEO Oncology to Present at the 8th Annual SVB Leerink Global Healthcare Conference
February 20 2019 - 7:00AM
Business Wire
AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey,
president and chief executive officer, will present at the 8th
Annual SVB Leerink Global Healthcare Conference in New York on
Wednesday, February 27, 2019 at 2:30 p.m. Eastern Time.
A live webcast of the presentation can be accessed by visiting
the investors section of the Company’s website at
www.aveooncology.com. A replay of the webcast will be archived for
30 days following the presentation date.
About AVEO
AVEO Pharmaceuticals, Inc. (the “Company” or “AVEO”) is a
biopharmaceutical company dedicated to advancing a broad portfolio
of targeted medicines for oncology and other areas of unmet medical
need. The Company’s strategy is to retain North American rights to
its oncology portfolio while securing partners in development and
commercialization outside of North America. The Company is seeking
to develop and commercialize its lead candidate tivozanib in North
America as a treatment for advanced or metastatic renal cell
carcinoma (“RCC”). The Company has outlicensed tivozanib (FOTIVDA®)
for oncological indications in Europe and other territories outside
of North America. Tivozanib is approved in the European Union, as
well as Norway and Iceland, for the first-line treatment of adult
patients with RCC and for adult patients who are vascular
endothelial growth factor receptor and mTOR pathway inhibitor-naïve
following disease progression after one prior treatment with
cytokine therapy for RCC. In addition, a new formulation of
tivozanib is being explored in ocular conditions. The Company has
entered into partnerships for the development and commercialization
of AV-203 (CAN017) and ficlatuzumab, both clinical stage assets in
oncology. The Company is currently seeking a partner to develop the
AV-353 platform, a preclinical asset, worldwide for the potential
treatment of pulmonary arterial hypertension and oncology. The
Company has recently regained the rights to its AV-380 program for
the potential treatment of cachexia and is initiating toxicology
studies to support the filing of an initial new drug application
and advance the program’s development.
For more information, please visit the Company’s website at
www.aveooncology.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO
that involve substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Actual results or events
could differ materially due to a number of important factors,
including risks discussed in the section titled “Risk Factors” in
AVEO’s most recent Annual Report on Form 10-K, its quarterly
reports on Form 10-Q and its other filings with the SEC. The
forward-looking statements in this press release represent AVEO’s
views as of the date of this press release. AVEO anticipates that
subsequent events and developments may cause its views to change.
While AVEO may elect to update these forward-looking statements at
some point in the future, it specifically disclaims any obligation
to do so. You should, therefore, not rely on these forward-looking
statements as representing AVEO’s views as of any date other than
the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190220005283/en/
AVEO:David Pitts, Argot Partners(212)
600-1902aveo@argotpartners.com
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From May 2024 to Jun 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Jun 2023 to Jun 2024